According to some conditions for granting EUA, the firm should submit safety, efficacy and immunogenicity data from ongoing clinical trials in India and Russia for a review to DCGI.
In FY 2025-26, AoN for 55 proposals amounting to Rs 6.73 lakh cr has been accorded by DAC. Both the quantum of AoN given and capital contracts signed, so far, have been the highest in any FY.
COMMENTS